Related Experiment Video
Updated: Jun 14, 2026
08:05
Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane
Published on: December 9, 2022
Vasoconstrictor prostanoids
Michel Félétou1, Yu Huang, Paul M Vanhoutte
1Institut Recherches Servier, Suresnes, France. michel.feletou@fr.netgrs.com
Pflugers Archiv : European Journal of Physiology
|March 25, 2010
Summary
Endothelial dysfunction in cardiovascular diseases involves thromboxane prostanoid (TP) receptors. Blocking these TP receptors can mitigate endothelial dysfunction, reduce blood clots, and prevent vascular inflammation.
Area of Science:
- Cardiovascular Science
- Vascular Biology
- Pharmacology
Background:
- Endothelial dysfunction, common in cardiovascular diseases and aging, is partly caused by endothelium-derived contracting factors opposing nitric oxide's vasodilatory effects.
- Endothelium-dependent contractions are mediated by cyclooxygenase activation and prostanoid release, which stimulate thromboxane prostanoid (TP) receptors on vascular smooth muscle.
Purpose of the Study:
- To investigate the role of thromboxane prostanoid (TP) receptors in endothelial dysfunction and related pathologies.
- To highlight the therapeutic potential of TP receptor antagonists in cardiovascular diseases.
Main Methods:
- The abstract does not specify methods but discusses the physiological and pathological roles of TP receptors and the effects of antagonists.
Main Results:
- TP receptor stimulation causes vascular smooth muscle contraction, proliferation, platelet aggregation, and endothelial inflammatory responses.
- TP receptor antagonists have shown efficacy in curtailing endothelial dysfunction in hypertension and diabetes.
- Antagonists act as antithrombotic agents and prevent vascular inflammation.
Conclusions:
- Thromboxane prostanoid (TP) receptors are key mediators of endothelial dysfunction and associated vascular pathologies.
- Targeting TP receptors with antagonists offers a promising therapeutic strategy for cardiovascular diseases, thrombosis, and inflammation.
Related Concept Videos
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
01:17Autoregulation of Blood Flow
Autoregulation mechanisms are characterized by their inherent capacity for self-regulation without necessitating specific nervous stimulation or endocrine control. These mechanisms facilitate the adjustment of blood flow and, therefore, perfusion specific to each tissue region. This self-regulation encompasses chemical signals and myogenic controls.
Chemical Signaling in Autoregulation
Chemical signaling operates at the precapillary sphincter level, inciting either contraction or relaxation.
Chemical Signaling in Autoregulation
Chemical signaling operates at the precapillary sphincter level, inciting either contraction or relaxation.
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...